hRpn13/ADRM1 links substrate recruitment with deubiquitination at the proteasome through its proteasome- and ubiquitin-binding Pru domain and DEUBAD domain, which binds and activates deubiquitinating enzyme (DUB) UCHL5/Uch37. Here, we edit the HCT116 colorectal cancer cell line to delete part of the hRpn13 Pru, producing cells that express truncated hRpn13 (trRpn13), which is competent for UCHL5 binding but defective for proteasome interaction. cells demonstrate reduced levels of proteasome-bound ubiquitinated proteins, indicating that the loss of hRpn13 function at proteasomes cannot be fully compensated for by the two other dedicated substrate receptors (hRpn1 and hRpn10). Previous studies indicated that the loss of full-length hRpn13 causes a corresponding reduction of UCHL5. We find UCHL5 levels unaltered in cells, but hRpn11 is elevated in and cells, perhaps from cell stress. Despite the ∼90 DUBs in human cells, including two others in addition to UCHL5 at the proteasome, we found deletion of UCHL5 from HCT116 cells to cause increased levels of ubiquitinated proteins in whole-cell extract and at proteasomes, suggesting that UCHL5 activity cannot be fully assumed by other DUBs. We also report anticancer molecule RA190, which binds covalently to hRpn13 and UCHL5, to require hRpn13 Pru and not UCHL5 for cytotoxicity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459265PMC
http://dx.doi.org/10.1128/MCB.00122-20DOI Listing

Publication Analysis

Top Keywords

hrpn13 pru
12
ubiquitinated proteins
12
uchl5
9
pru uchl5
8
uchl5 proteasome
8
hrpn13
7
cells
6
impact losing
4
losing hrpn13
4
pru
4

Similar Publications

A structure-based designed small molecule depletes hRpn13 and a select group of KEN box proteins.

Nat Commun

March 2024

Protein Processing Section, Center for Structural Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.

Proteasome subunit hRpn13 is partially proteolyzed in certain cancer cell types to generate hRpn13 by degradation of its UCHL5/Uch37-binding DEUBAD domain and retention of an intact proteasome- and ubiquitin-binding Pru domain. By using structure-guided virtual screening, we identify an hRpn13 binder (XL44) and solve its structure ligated to hRpn13 Pru by integrated X-ray crystallography and NMR to reveal its targeting mechanism. Surprisingly, hRpn13 is depleted in myeloma cells following treatment with XL44.

View Article and Find Full Text PDF

Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma.

Nat Commun

December 2021

Protein Processing Section, Center for Structural Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA.

Article Synopsis
  • - Researchers have identified hRpn13 as a new target for anti-cancer therapies, particularly for multiple myeloma, using computational and biophysical methods to discover a chemical scaffold that binds to hRpn13 mimicking proteasome interactions.
  • - The lead compound XL5 effectively fits into a specific pocket of hRpn13, allowing for the development of Proteolysis Targeting Chimeras (PROTACs) that can trigger the target's ubiquitination and promote cancer cell death.
  • - Experiments showed that hRpn13 is essential for the apoptosis initiated by XL5-PROTACs, highlighting its potential as a valuable target for developing treatments against cancers that produce this protein.
View Article and Find Full Text PDF

Impact of Losing hRpn13 Pru or UCHL5 on Proteasome Clearance of Ubiquitinated Proteins and RA190 Cytotoxicity.

Mol Cell Biol

August 2020

Protein Processing Section, Structural Biophysics Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA

hRpn13/ADRM1 links substrate recruitment with deubiquitination at the proteasome through its proteasome- and ubiquitin-binding Pru domain and DEUBAD domain, which binds and activates deubiquitinating enzyme (DUB) UCHL5/Uch37. Here, we edit the HCT116 colorectal cancer cell line to delete part of the hRpn13 Pru, producing cells that express truncated hRpn13 (trRpn13), which is competent for UCHL5 binding but defective for proteasome interaction. cells demonstrate reduced levels of proteasome-bound ubiquitinated proteins, indicating that the loss of hRpn13 function at proteasomes cannot be fully compensated for by the two other dedicated substrate receptors (hRpn1 and hRpn10).

View Article and Find Full Text PDF

An Extended Conformation for K48 Ubiquitin Chains Revealed by the hRpn2:Rpn13:K48-Diubiquitin Structure.

Structure

May 2020

Protein Processing Section, Structural Biophysics Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA. Electronic address:

Rpn13/Adrm1 is recruited to the proteasome by PSMD1/Rpn2, where it serves as a substrate receptor that binds preferentially to K48-linked ubiquitin chains, an established signal for protein proteolysis. Here, we use NMR to solve the structure of hRpn13 Pru:hRpn2 (940-953):K48-diubiquitin. Surprisingly, hRpn2-bound hRpn13 selects a dynamic, extended conformation of K48-diubiquitin that is unique from previously determined structures.

View Article and Find Full Text PDF

Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets.

Nat Commun

June 2017

Protein Processing Section, Structural Biophysics Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, USA.

Article Synopsis
  • The proteasome-ubiquitin receptor hRpn13/Adrm1 activates the deubiquitinating enzyme Uch37, with bis-benzylidine piperidone RA190 inhibiting cancer growth in mice by targeting this interaction.
  • Structural analysis shows hRpn13 and hRpn2 interact closely, with an extension of hRpn2 blocking RA190's binding site on hRpn13.
  • RA190 does not impact hRpn13's connection with Uch37 but instead directly inactivates Uch37, leading to a buildup of substrates at proteasomes in hRpn13-deficient cells.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!